A Study on the Clinical Efficacy and Safety of Telitacicept Combined With Baricitinib in the Treatment of Difficult-to-Treat Rheumatoid Arthritis (D2T RA)
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
The aim of this study is to observe the clinical efficacy and safety of telitacicept combined with baricitinib in the treatment of D2TRA patients
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 85
View:
• 1\. Age 18-85 years
• 2\. Diagnosed with refractory rheumatoid arthritis according to the 2021 EULAR (European Alliance of Associations for Rheumatology) diagnostic criteria
• 3\. The traditional disease-improving rheumatic drug treatment is ineffective, and the use of two or more biological/targeted disease improving anti-rheumatic drugs is ineffective, and telitacicept combined with tofacitinib is required treated patients
• 4\. Voluntarily provided written informed consent
Locations
Other Locations
China
Zhejiang Provincial People's Hospital
RECRUITING
Hangzhou
Contact Information
Primary
Zhenhua Ying
yingzh2021@163.com
+86-571-3989897128
Time Frame
Start Date: 2026-03-01
Estimated Completion Date: 2028-03-30
Participants
Target number of participants: 30
Treatments
Telitacicept; Baricitinib. One group of D2TRA subjects receive Telitacicept combine Baricitinib
Related Therapeutic Areas
Sponsors
Leads: Zhejiang Provincial People's Hospital